Matisse Pharmaceuticals

Matisse Pharmaceuticals B.V.

This biopharmaceutical company develops heparin-derived medicinal therapies to treat sepsis and septic shock for patients in intensive care units.

Modus Therapeutics

This biotechnology company develops sevuparin to treat patients suffering from sepsis, septic shock, severe malaria and chronic systemic inflammation.

Inotrem

This biopharmaceutical company develops immunotherapies targeting the TREM-1 pathway for patients suffering from acute inflammatory syndromes such as septic shock.

PATH EX, Inc.

This company develops a medical device that removes bacteria and endotoxins from the bloodstream to treat sepsis patients in clinical settings.

AM Pharma

This biopharmaceutical company develops recombinant human alkaline phosphatase therapeutics to treat patients suffering from sepsis-associated acute kidney injury and other severe inflammatory conditions.

Adrenomed

This biopharmaceutical company develops monoclonal antibody therapies to restore vascular integrity for critically ill patients suffering from sepsis and septic shock.

Hemotune

This company develops a magnetic blood purification platform using nanoengineered beads to remove specific disease-causing substances for patients with sepsis or requiring gene therapy.

Aplagon

This company develops heparin proteoglycan mimetics to treat thrombo-inflammatory diseases in patients with cardiovascular conditions such as chronic limb-threatening ischaemia.